Radiopharmaceuticals Market

Radiopharmaceuticals Market (Compound: Fluorine-18 Derivatives, Technetium-99, Lutetium [Lu] 177, Gallium-68, Zirconium 89, 11C-choline, 14C-urea, and Others; System: PET and SPECT; Indication: Oncology, Neurology, Cardiology, and Others; and End-user: Hospitals, Diagnostic Labs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021 - 2031

On the basis of end-use application, the global radiopharmaceuticals market is divided into two different types, including diagnostic centers and hospitals. Due to the substantial availability of competent medical practitioners in hospital radiology departments, the hospital segment is expected to hold a considerable share of this market during the forecast period. However, the growing number of diagnostic centers, particularly in developed nations such as the U.S. is likely to propel the global radiopharmaceuticals market forward over the forecast period, from 2021 to 2031

Radiopharmaceuticals are a class of radioactive substances that can be employed for diagnostic or therapeutic purposes. Chemicals that emit beta particles (positrons or electrons) or gamma rays are often employed for diagnostic purposes, whereas compounds that release Auger electrons or alpha particles are typically utilized for therapeutic purposes. Radiopharmaceuticals are referred to as "tracers" when they are utilized for diagnostic reasons. The quantity of radiation in diagnostic radiopharmaceuticals is lower than in therapy radiopharmaceuticals.

Radiopharmaceuticals are basically unique therapeutic compositions that incorporate radioisotopes. These radiopharmaceuticals are utilized for both diagnosis and treatment. Radiopharmaceuticals are classified into four different categories, which are radiopharmaceutical preparation, radionuclide generator, radiopharmaceutical precursor, and radiopharmaceutical preparation kit.

To know the scope of our report Get a Sample of the Radiopharmaceutical Market

A rise in Research and Development Activities is Expected to Drive Demand in the Market

The global radiopharmaceuticals market is driven by the rise in patient awareness, demand for precise diagnosis, increasing demand for disease-targeted cancer therapy, and the growing uses of molecular imaging. The utilization of monoclonal antibodies and radiolabeled peptides for the identification and treatment of malignant tumors (referred to as radiopharmaceutical-based customized therapy) is likely to fuel the growth of the global market for radiopharmaceuticals. The market research report examines the radiopharmaceutical sector in further depth, offering a comprehensive view of market dynamics, patient preferences, illness trends, and supply and demand.

In the last few decades, nuclear medicine has acquired a lot of popularity. The availability of 99m Tc, an isotope used in 80% of diagnostic procedures, is primarily responsible for nuclear medicine's expanding popularity. At present, about 25 million diagnostic procedures involving 99m Tc radiopharmaceuticals are performed yearly, with trends indicating that this number is likely to rise. The availability of short-lived 99m Tc is one of the key factors likely to drive the adoption of Technetium 99. At present, research and development operations are in full swing to boost 99 Mo's total production capacity, which is expected to have a beneficial influence on 99m Tc output.

Get a glimpse of the in-depth analysis through our Report Brochure

In the current situation, 99m Tc is widely employed in a variety of diagnostic procedures, such as neuroendocrine tumor imaging and thyroid uptake pertechnetate. In the last few years, there has been a tremendous increase in research activity aimed at developing new and better 99m Tc radiopharmaceuticals. 99m Tc is predicted to dominate the global radiopharmaceutical market throughout the forecast timeframe, from 2021 to 20321, as applications of 99m Tc for dynamic and morphological imaging of the liver, kidneys, and bone are expected to rise. In addition, due to their widespread availability and low prices, various radiopharmaceuticals are expected to gain popularity.

radiopharmaceutical market segmentation

Expanding operations in the future? To get the perfect launch to ask for a custom report

Increasing Demand for Risk Assessment Services for Cancer Treatment to Drive North America and Europe Markets

North America, Latin America, Asia Pacific, Europe, the Middle East, and Africa are the four primary regions that make up the global radiopharmaceuticals business. In 2020, the global radiopharmaceuticals market was headed by North America, trailed by Europe. Due to a rise in PET-CT scanner equipment installations and increased demand for disease risk assessment services for cancer treatment, North America held a large part of the global market for radiopharmaceuticals in 2020. From 2021 to 2031, the radiopharmaceuticals market in Asia Pacific is expected to rise at a rapid growth rate. The global market in the region is expected to be driven by product launches, acquisitions, distribution agreements, partnerships, and regional growth by local companies, particularly in India and China.

Radiopharmaceuticals Market - Segmentation

TMR’s study on the global radiopharmaceuticals market includes information divided into five segments: compound, indication, system, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global market have been discussed in detail.

Compound
  • Fluorine-18 derivatives
    • Fluorine-18 Fludeoxyglucose (FDG)
    • Fluorine-18 Sodium Fluoride
    • Fluorine-18 Flucicovine
    • Fluorine-18 Florbetapir
    • Fluorine-18 Florbetaben
    • Others
  • Technetium-99
  • Lutetium (Lu) 177
  • Gallium-68
    • Dotatate
    • Dotatoc
  • Zirconium 89
  • 11C-choline
  • 14C-urea
  • Others
System
  • PET
    • Standalone PET Systems
    • Hybrid PET/CT
    • Hybrid PET/MRI
  • SPECT
Indication
  • Oncology
  • Neurology
    • Neurodegenerative Diseases (AD, PD, and Others)
    • Epilepsy
  • Cardiology
  • Others
End-user
  • Hospitals
  • Diagnostic Labs
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Frequently Asked Questions

What is the total market worth of Radiopharmaceuticals Market?

The global market is projected to reach a value of US$ 8.5 Bn by 2031 end

What is the anticipated CAGR of the Radiopharmaceuticals Industry in the forecast period?

The market for radiopharmaceuticals is anticipated to grow at a CAGR of 7.3% during the forecast period

What are the end-use segments in the Radiopharmaceuticals Market?

The end-user segments in the global market are hospitals, diagnostic labs, and others

Which is the rising prominent segment in the Radiopharmaceuticals business?

The tc-99 segment is anticipated to account for a major share of the global market for radiopharmaceuticals by 2031

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Radiopharmaceuticals Market

    4. Market Overview

        4.1. Introduction & Overview

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunities

        4.3. Global Radiopharmaceuticals Market Analysis and Forecast, 2017–2031

    5. Market Outlook

        5.1. COVID-19 Pandemics Impact on Industry

        5.2. Key Industry Events

        5.3. No. of Nuclear Medicine Centers in Major Countries

        5.4. List of FDA Approved Radioisotopes

    6. Global Radiopharmaceuticals Market Analysis and Forecast, by Compound

        6.1. Introduction & Definition

        6.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

            6.2.1. Fluorine-18 Derivatives

                6.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

                6.2.1.2. Fluorine-18 Sodium Fluoride

                6.2.1.3. Fluorine-18 Flucicovine

                6.2.1.4. Fluorine-18 Florbetapir

                6.2.1.5. Fluorine-18 Florbetaben

                6.2.1.6. Others

            6.2.2. Technetium-99

            6.2.3. Lutetium (Lu) 177

            6.2.4. Gallium-68

                6.2.4.1. Dotatate

                6.2.4.2. Dotatoc

            6.2.5. Zirconium 89

            6.2.6. 11C-choline

            6.2.7. 14C-urea

            6.2.8. Others

        6.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound

    7. Global Radiopharmaceuticals Market Analysis and Forecast, by Indication

        7.1. Introduction & Definition

        7.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

            7.2.1. Diagnosis

            7.2.2. Neurology

                7.2.2.1. Neurodegenerative Disease (AD, PD, and Others)

                7.2.2.2. Epilepsy

            7.2.3. Cardiology

            7.2.4. Others

        7.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication

    8. Global Radiopharmaceuticals Market Analysis and Forecast, by System

        8.1. Introduction & Definition

        8.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

            8.2.1. PET

                8.2.1.1. Standalone PET systems

                8.2.1.2. Hybrid PET/CT

                8.2.1.3. Hybrid PET/MRI

            8.2.2. SPECT

        8.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by System

    9. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

        9.1. Introduction & Definition

        9.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

            9.2.1. Hospitals

            9.2.2. Diagnostic Labs

            9.2.3. Others

        9.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user

    10. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Rest of the World

        10.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Region

    11. North America Radiopharmaceuticals Market Analysis and Forecast

        11.1. Introduction

        11.2. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

            11.2.1. Fluorine-18 Derivatives

                11.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

                11.2.1.2. Fluorine-18 Sodium Fluoride

                11.2.1.3. Fluorine-18 Flucicovine

                11.2.1.4. Fluorine-18 Florbetapir

                11.2.1.5. Fluorine-18 Florbetaben

                11.2.1.6. Others

            11.2.2. Technetium-99

            11.2.3. Lutetium (Lu) 177

            11.2.4. Gallium-68

                11.2.4.1. Dotatate

                11.2.4.2. Dotatoc

            11.2.5. Zirconium 89

            11.2.6. 11C-choline

            11.2.7. 14C-urea

            11.2.8. Others

        11.3. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

            11.3.1. Diagnosis

            11.3.2. Neurology

                11.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

                11.3.2.2. Epilepsy

            11.3.3. Cardiology

            11.3.4. Others

        11.4. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

            11.4.1. PET

                11.4.1.1. Standalone PET systems

                11.4.1.2. Hybrid PET/CT

                11.4.1.3. Hybrid PET/MRI

            11.4.2. SPECT

        11.5. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

            11.5.1. Hospitals

            11.5.2. Diagnostic Labs

            11.5.3. Others

        11.6. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. North America PET-CT Scanner Devices Market Attractiveness Analysis

            11.7.1. By Compound

            11.7.2. By Indication

            11.7.3. By System

            11.7.4. End-user

            11.7.5. By Country

    12. Europe Radiopharmaceuticals Market Analysis and Forecast

        12.1. Introduction

        12.2. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

            12.2.1. Fluorine-18 Derivatives

                12.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

                12.2.1.2. Fluorine-18 Sodium Fluoride

                12.2.1.3. Fluorine-18 Flucicovine

                12.2.1.4. Fluorine-18 Florbetapir

                12.2.1.5. Fluorine-18 Florbetaben

                12.2.1.6. Others

            12.2.2. Technetium-99

            12.2.3. Lutetium (Lu) 177

            12.2.4. Gallium-68

                12.2.4.1. Dotatate

                12.2.4.2. Dotatoc

            12.2.5. Zirconium 89

            12.2.6. 11C-choline

            12.2.7. 14C-urea

            12.2.8. Others

        12.3. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

            12.3.1. Diagnosis

            12.3.2. Neurology

                12.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

                12.3.2.2. Epilepsy

            12.3.3. Cardiology

            12.3.4. Others

        12.4. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

            12.4.1. PET

                12.4.1.1. Standalone PET systems

                12.4.1.2. Hybrid PET/CT

                12.4.1.3. Hybrid PET/MRI

            12.4.2. SPECT

        12.5. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

            12.5.1. Hospitals

            12.5.2. Diagnostic Labs

            12.5.3. Others

        12.6. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Europe Radiopharmaceuticals Market Attractiveness Analysis

            12.7.1. By Compound

            12.7.2. By Indication

            12.7.3. By Systems

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

        13.1. Introduction

        13.2. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

            13.2.1. Fluorine-18 Derivatives

                13.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

                13.2.1.2. Fluorine-18 Sodium Fluoride

                13.2.1.3. Fluorine-18 Flucicovine

                13.2.1.4. Fluorine-18 Florbetapir

                13.2.1.5. Fluorine-18 Florbetaben

                13.2.1.6. Others

            13.2.2. Technetium-99

            13.2.3. Lutetium (Lu) 177

            13.2.4. Gallium-68

                13.2.4.1. Dotatate

                13.2.4.2. Dotatoc

            13.2.5. Zirconium 89

            13.2.6. 11C-choline

            13.2.7. 14C-urea

            13.2.8. Others

        13.3. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

            13.3.1. Diagnosis

            13.3.2. Neurology

                13.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

                13.3.2.2. Epilepsy

            13.3.3. Cardiology

            13.3.4. Others

        13.4. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

            13.4.1. PET

                13.4.1.1. Standalone PET systems

                13.4.1.2. Hybrid PET/CT

                13.4.1.3. Hybrid PET/MRI

            13.4.2. SPECT

        13.5. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

            13.5.1. Hospitals

            13.5.2. Diagnostic Labs

            13.5.3. Others

        13.6. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis

            13.7.1. By Compound

            13.7.2. By Indication

            13.7.3. By Systems

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Rest of the World Radiopharmaceuticals Market Analysis and Forecast

        14.1. Introduction

        14.2. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

            14.2.1. Fluorine-18 Derivatives

                14.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

                14.2.1.2. Fluorine-18 Sodium Fluoride

                14.2.1.3. Fluorine-18 Flucicovine

                14.2.1.4. Fluorine-18 Florbetapir

                14.2.1.5. Fluorine-18 Florbetaben

                14.2.1.6. Others

            14.2.2. Technetium-99

            14.2.3. Lutetium (Lu) 177

            14.2.4. Gallium-68

                14.2.4.1. Dotatate

                14.2.4.2. Dotatoc

            14.2.5. Zirconium 89

            14.2.6. 11C-choline

            14.2.7. 14C-urea

            14.2.8. Others

        14.3. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

            14.3.1. Diagnosis

            14.3.2. Neurology

                14.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

                14.3.2.2. Epilepsy

            14.3.3. Cardiology

            14.3.4. Others

        14.4. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

            14.4.1. PET

                14.4.1.1. Standalone PET systems

                14.4.1.2. Hybrid PET/CT

                14.4.1.3. Hybrid PET/MRI

            14.4.2. SPECT

        14.5. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

            14.5.1. Hospitals

            14.5.2. Diagnostic Labs

            14.5.3. Others

        14.6. Rest of the World Radiopharmaceuticals Market Attractiveness Analysis

            14.6.1. By Compound

            14.6.2. By Indication

            14.6.3. By System

            14.6.4. By End-user

    15. Competition Landscape

        15.1. Company Profiles

            15.1.1. Advanced Accelerator Applications (a Novartis AG Company)

                15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.1.2. Growth Strategies

                15.1.1.3. SWOT Analysis

            15.1.2. Siemens Healthineers AG

                15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.2.2. Growth Strategies

                15.1.2.3. SWOT Analysis

            15.1.3. Jubilant Pharma Limited

                15.1.3.1. Company Overview (HQ, Business Segments)

                15.1.3.2. Growth Strategies

                15.1.3.3. SWOT Analysis

            15.1.4. GE Healthcare

                15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.4.2. Growth Strategies

                15.1.4.3. SWOT Analysis

            15.1.5. Bayer AG

                15.1.5.1. Company Overview (HQ, Business Segments)

                15.1.5.2. Growth Strategies

                15.1.5.3. SWOT Analysis

            15.1.6. ITM Isotopen Technologien München AG

                15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.6.2. Growth Strategies

                15.1.6.3. SWOT Analysis

            15.1.7. Telix Pharmaceuticals

                15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.7.2. Growth Strategies

                15.1.7.3. SWOT Analysis

            15.1.8. Lantheus Holdings, Inc.

                15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.8.2. Growth Strategies

                15.1.8.3. SWOT Analysis

            15.1.9. Eli Lilly and Company

                15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.9.2. Growth Strategies

                15.1.9.3. SWOT Analysis

            15.1.10. Nihon Medi-Physics

                15.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.10.2. Growth Strategies

                15.1.10.3. SWOT Analysis

            15.1.11. Avanos Medical, Inc.

                15.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.1.11.2. Growth Strategies

                15.1.11.3. SWOT Analysis

    List of Tables

    Table 01: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Compound, 2017–2031

    Table 02: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

    Table 03: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Gallium-68, 2017–2031

    Table 04: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

    Table 05: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

    Table 06: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 07: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

    Table 08: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 09: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 10: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 11: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

    Table 12: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

    Table 13: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

    Table 14: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

    Table 15: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System (PET), 2017–2031

    Table 16: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 17: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

    Table 18: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 19: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 20: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031 

    Table 21: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

    Table 22: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

    Table 23: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

    Table 24: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

    Table 25: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 26: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

    Table 27: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 28: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 29: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

    Table 30: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

    Table 31: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

    Table 32: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

    Table 33: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

    Table 34: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 35: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

    Table 36: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 37: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

    Table 38: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

    Table 39: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

    Table 40: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

    Table 41: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

    Table 42: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 43: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

    Table 44: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 02: Global PET-CT Scanner Devices Market Value Share, by Region, 2020

    Figure 03: Global Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

    Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Technetium-99, 2017–2031

    Figure 05: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Gallium-68, 2017–2031

    Figure 06: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Fluorine-18 Derivatives, 2017–2031

    Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Lu-177, 2017–2031

    Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Zirconium89, 2017–2031

    Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 11C-choline, 2017–2031

    Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 14C-urea, 2017–2031

    Figure 11: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

    Figure 13: Global Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

    Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Mn), by PET, 2017–2031

    Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Mn), by SPECT, 2017–2031

    Figure 16: Global Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

    Figure 17: Global Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 18: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Oncology, 2017–2031

    Figure 19: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Cardiology, 2017–2031

    Figure 20: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Neurology, 2017–2031

    Figure 21: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 22: Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 23: Global Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 24: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Diagnostic Lab, 2017–2031

    Figure 25: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Hospitals, 2017–2031

    Figure 26: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 27: Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021 -2031

    Figure 28: Global Radiopharmaceuticals Market Value Share Analysis, by Region, 2020 and 2031

    Figure 29: Global Radiopharmaceuticals Market Attractiveness Analysis, by Region, 2021–2031

    Figure 30: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

    Figure 31: North America Radiopharmaceuticals Market Value Share Analysis, by Country, 2020 and 2031

    Figure 32: North America Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2021–2031

    Figure 33: North America Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

    Figure 34: North America Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

    Figure 35: North America Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

    Figure 36: North America Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

    Figure 37: North America Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 38: North America Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 39: North America Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 40: North America Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031 

    Figure 41: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

    Figure 42: Europe Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 43: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 44: Europe Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

    Figure 45: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

    Figure 46: Europe Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

    Figure 47: Europe Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

    Figure 48: Europe Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 49: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 50: Europe Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 51: Europe Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 52: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

    Figure 53: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 54: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 55: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

    Figure 56: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

    Figure 57: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

    Figure 58: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

    Figure 59: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 60: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031 

    Figure 61: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 62: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 63: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

    Figure 64: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

    Figure 65: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

    Figure 66: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

    Figure 67: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

    Figure 68: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 69: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 70: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 71: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031 

Copyright © Transparency Market Research, Inc. All Rights reserved